CD8A and sarcoma: DRibbles efficiently cross-prime antigen-specific naïve CD8+ and CD4+ T cells in vitro and in vivo; and immunotherapy with DRibbles isolated from a variety of murine tumor cell lines is protective or therapeutic in mice bearing established melanomas, lung carcinomas, breast carcinomas, and sarcomas [10,11].